Trial · Interventional

CompletedPhase 3Results postedRegistry data

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight

Short name SURMOUNT-1

NCTNCT04184622Other id17244Other idI8F-MC-GPHK

Open at ClinicalTrials.govAsk about this trial

Overview

Status: Completed
Phase: Phase 3
Enrollment: 2,539 participants (actual)
Sponsor: Eli Lilly and Company · Industry
Design: Randomized · Double masking
Countries: 10 countries
United States, Argentina, Brazil, China, India, Japan, Mexico, Puerto Rico, Russia, Taiwan
Start: 4 Dec 2019
Primary completion: 1 Apr 2022
Completion: 6 Jul 2024
First posted: 3 Dec 2019
Last update posted: 24 Jul 2025
Conditions: Overweight · Obesity

Timeline

1 trial · 1 completed · 1 with posted results

Completed
Ongoing
Not yet recruiting
Stopped
Estimated dates (est.)
Results posted

2019202020212022202320242025

Ph 3
SURMOUNT-1
NCT04184622
4 Dec 2019 to 6 Jul 2024

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

This is a study of tirzepatide in participants with overweight and obesity. The main purpose is to learn more about how tirzepatide affects body weight. The study has two phases: A main phase and an extension phase. The main phase of the study will last 72 weeks. Participants with prediabetes will continue in the extension for another 2 years.

Interventions

TirzepatideDrug
PlaceboDrug

Arms4

Placebo comparator
Placebo
* Primary Treatment Period (Week 0-Week 72): Participants with normoglycemia or prediabetes at the time of randomization received once weekly (QW) subcutaneous (SC) doses of a matching placebo, administered over a period of 72 weeks. * Additional Treatment Period (Week 72-Week 176): At week 72, only participants who had prediabetes at the time of randomization and had completed the primary treatment period continued receiving the placebo dose SC QW until week 176. * Safety Follow-up Period: Participants who had completed or discontinued the primary treatment period were followed for safety for 4 weeks (weeks 72 - week 76), and those who had completed or discontinued the additional treatment period (prediabetes at randomization) were followed for 17 weeks (week 176 - week 193). No treatment was administered during this period.
Experimental
5 mg Tirzepatide
* Primary Treatment Period (Week 0-Week 72): Participants with normoglycemia or prediabetes at the time of randomization received QW SC doses of tirzepatide, starting at 2.5 milligrams (mg) and increasing by 2.5 mg every 4 weeks until reaching a dose of 5 mg, which was then maintained up to week 72. * Additional Treatment Period (Week 72-Week 176): At week 72, only participants who had prediabetes at the time of randomization and had completed the primary treatment period continued receiving the 5 mg tirzepatide dose SC QW until week 176. * Safety Follow-up Period: Participants who had completed or discontinued the primary treatment period were followed for safety for 4 weeks (weeks 72 - week 76), and those who had completed or discontinued the additional treatment period (prediabetes at randomization) were followed for 17 weeks (week 176 - week 193). No treatment was administered during this period.
Experimental
10 mg Tirzepatide
* Primary Treatment Period (Week 0-Week 72): Participants with normoglycemia or prediabetes at the time of randomization received QW SC doses of tirzepatide, starting at 2.5 mg and increasing by 2.5 mg every 4 weeks until reaching a dose of 10 mg, which was then maintained up to week 72. * Additional Treatment Period (Week 72-Week 176): At week 72, only participants who had prediabetes at the time of randomization and had completed the primary treatment period continued receiving the 10 mg tirzepatide dose SC QW until week 176. * Safety Follow-up Period: Participants who had completed or discontinued the primary treatment period were followed for safety for 4 weeks (weeks 72 - week 76), and those who had completed or discontinued the additional treatment period (prediabetes at randomization) were followed for 17 weeks (week 176 - week 193). No treatment was administered during this period.
Experimental
15 mg Tirzepatide
* Primary Treatment Period (Week 0-Week 72): Participants with normoglycemia or prediabetes at the time of randomization received QW SC doses of tirzepatide, starting at 2.5 mg and increasing by 2.5 mg every 4 weeks until reaching a dose of 15 mg, which was then maintained up to week 72. * Additional Treatment Period (Week 72-Week 176): At week 72, only participants who had prediabetes at the time of randomization and had completed the primary treatment period continued receiving the 15 mg tirzepatide dose SC QW until week 176. * Safety Follow-up Period: Participants who had completed or discontinued the primary treatment period were followed for safety for 4 weeks (weeks 72 - week 76), and those who had completed or discontinued the additional treatment period (prediabetes at randomization) were followed for 17 weeks (week 176 - week 193). No treatment was administered during this period.

Primary outcomes2

Outcomes the sponsor listed as primary.

Percent Change From Baseline in Body Weight (Primary Treatment Period)
Time frame · Baseline, Week 72
Registry description
Least Squares (LS) Mean was calculated using mixed-model repeated measures (MMRM) with baseline, analysis country, sex, prediabetes status at randomization, treatment, time, treatment\*time (Type III sum of squares) in the model.
Percentage of Participants Who Achieve ≥5% Body Weight Reduction (Primary Treatment Period)
Time frame · Week 72
Registry description
Percentage of participants who achieve greater than or equal to( ≥) 5% body weight reduction.

Secondary outcomes(20)

Change From Baseline in Body Weight (Pooled Doses of Tirzepatide 10 mg and 15 mg) - Primary Treatment Period
Time frame · Baseline, Week 20
Registry description
LS Mean was calculated using MMRM with baseline, analysis country, sex, prediabetes status at randomization, treatment, time, treatment\*time (Type III sum of squares) in the model.
Percentage of Participants Who Achieve ≥10% Body Weight Reduction (Primary Treatment Period)
Time frame · Week 72
Registry description
Percentage of Participants who Achieve ≥10% Body Weight Reduction
Percentage of Participants Who Achieve ≥15% Body Weight Reduction (Primary Treatment Period)
Time frame · Week 72
Registry description
Percentage of participants who achieve ≥15% body weight reduction.
Percentage of Participants Who Achieve ≥20% Body Weight Reduction (Primary Treatment Period)
Time frame · Week 72
Registry description
Percentage of participants who achieve ≥20% body weight reduction.
Change From Baseline in Waist Circumference (Primary Treatment Period)
Time frame · Baseline, Week 72
Registry description
LS Mean was calculated using MMRM with baseline, analysis country, sex, prediabetes status at randomization, treatment, time, treatment\*time (Type III sum of squares) in the model.
Change From Baseline in Short Form Survey-36 Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score at Week 72 (Pooled Doses of Tirzepatide 10 mg and 15 mg) - Primary Treatment Period
Time frame · Baseline, Week 72
Registry description
The SF-36v2 acute, 1-week recall version is a 36-item, generic, patient-administered measure designed to assess the following 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The Physical-Functioning domain assesses limitations due to health "now" while the remaining domains assess functioning "in the past week." Each domain is scored individually and information from these 8 domains are further aggregated into 2 health-component summary scores: Physical-Component Summary and Mental-Component Summary. Items are answered on Likert scales of varying lengths (3-, 5-, or 6- point scales).The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health.
Percent Change From Baseline in Triglycerides (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg) - Primary Treatment Period
Time frame · Baseline, Week 72
Registry description
Percent change from baseline in triglycerides are reported as model-based estimate and Standard Error (SE) from MMRM analysis using log transformation.
Percent Change From Baseline in Total Cholesterol (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg) - Primary Treatment Period
Time frame · Baseline, Week 72
Registry description
Results are reported as model-based estimate and SE from MMRM analysis using log transformation.
Percent Change From Baseline in High-Density Lipoprotein (HDL) Cholesterol at Week 72 (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg) - Primary Treatment Period
Time frame · Baseline, Week 72
Registry description
Results are reported as model-based estimate and SE from MMRM analysis using log transformation.
Change From Baseline in Systolic Blood Pressure (SBP) (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg) - Primary Treatment Period
Time frame · Baseline, Week 72
Registry description
LS Mean was calculated using MMRM with baseline, analysis country, sex, prediabetes status at randomization, treatment, time, treatment\*time (Type III sum of squares) in the model.
Percent Change From Baseline in Fasting Insulin (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg) - Primary Treatment Period
Time frame · Baseline, Week 72
Registry description
Fasting Insulin is a test used to measure the amount of insulin in the body. Results are reported as model-based estimates and SE from MMRM analysis using log transformation.
Percent Change From Baseline in Body Weight (Primary and Additional Treatment Periods : Participants With Prediabetes at Randomization)
Time frame · Baseline, Week 176
Registry description
LS Mean was calculated using mixed-model repeated measures (MMRM) with baseline, analysis country, sex, treatment, time, treatment\*time (Type III sum of squares) in the model.
Percentage of Participants With Onset of Type 2 Diabetes From Baseline to Week 176 (Primary and Additional Treatment Periods: Participants With Prediabetes at Randomization)
Time frame · Baseline through Week 176
Registry description
The percentage of participants with onset of Type 2 diabetes mellitus (T2DM), evaluated as time to onset of T2DM among those who had pre-diabetes at randomization, was reported. Time to onset of Type 2 diabetes mellitus was defined as the duration from the date of randomization to the adjudication committee-confirmed date of incident diabetes. Participants who did not experience the event were censored.
Percentage of Participants With Onset of Type 2 Diabetes From Baseline to Week 193 (Primary and Additional Treatment Periods + Safety Follow-up Period: Participants With Prediabetes at Randomization)
Time frame · Baseline through Week 193
Registry description
The percentage of participants with onset of Type 2 diabetes mellitus (T2DM), evaluated as time to onset of T2DM among those who had pre-diabetes at randomization, was reported. Time to onset of Type 2 diabetes mellitus was defined as the duration from the date of randomization to the adjudication committee-confirmed date of incident diabetes. Participants who did not experience the event were censored.
Change From Baseline in Body Mass Index (BMI) - Primary Treatment Period
Time frame · Baseline, Week 72
Registry description
LS Mean was calculated using MMRM with baseline, analysis country, sex, prediabetes status at randomization, treatment, time, treatment\*time (Type III sum of squares) in the model.
Change From Baseline in Hemoglobin A1c (HbA1c) - Primary Treatment Period
Time frame · Baseline, Week 72
Registry description
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. LS Mean was calculated using MMRM with baseline, analysis country, sex, prediabetes status at randomization, treatment, time, treatment\*time (Type III sum of squares) in the model.
Change From Baseline in Fasting Glucose (Primary Treatment Period)
Time frame · Baseline, Week 72
Registry description
LS Mean was calculated using MMRM with baseline, analysis country, sex, prediabetes status at randomization, treatment, time, treatment\*time (Type III sum of squares) in the model.
Percent Change From Baseline in Low-Density Lipoprotein (LDL) Cholesterol (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg) - Primary Treatment Period
Time frame · Baseline, Week 72
Registry description
Results are reported as model-based estimate and SE from MMRM analysis using log transformation.
Percent Change From Baseline in Very Low-Density Lipoprotein (VLDL) Cholesterol (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg) - Primary Treatment Period
Time frame · Baseline, Week 72
Registry description
Results are reported as model-based estimate and SE from MMRM analysis using log transformation.
Percent Change From Baseline in Free Fatty Acids (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg) - Primary Treatment Period
Time frame · Baseline, Week 72
Registry description
Results are reported as model-based estimate and SE from MMRM analysis using log transformation.

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

Primary outcome results

Primary outcomeLeast squares mean· Baseline, Week 72

Percent Change From Baseline in Body Weight (Primary Treatment Period)

Group	Value (percent change)	Spread
Placebo	-2.4	0.40
5 mg Tirzepatide	-16.0	0.39
10 mg Tirzepatide	-21.4	0.39
15 mg Tirzepatide	-22.5	0.39

Primary outcomeNumber· Week 72

Percentage of Participants Who Achieve ≥5% Body Weight Reduction (Primary Treatment Period)

Group	Value (Percentage of Participants)
Placebo	27.87
5 mg Tirzepatide	89.41
10 mg Tirzepatide	96.18
15 mg Tirzepatide	96.32

Secondary and other outcome results(6)

Secondary outcomeLeast squares mean· Baseline, Week 20

Change From Baseline in Body Weight (Pooled Doses of Tirzepatide 10 mg and 15 mg) - Primary Treatment Period

Group	Value (kilograms)	Spread
Placebo	-2.5	0.22
Pooled 10 mg/15 mg Tirzepatide	-13.2	0.16

Secondary outcomeNumber· Week 72

Percentage of Participants Who Achieve ≥10% Body Weight Reduction (Primary Treatment Period)

Group	Value (Percentage of Participants)
Placebo	13.54
5 mg Tirzepatide	73.35
10 mg Tirzepatide	85.85
15 mg Tirzepatide	90.08

Secondary outcomeNumber· Week 72

Percentage of Participants Who Achieve ≥15% Body Weight Reduction (Primary Treatment Period)

Group	Value (Percentage of Participants)
Placebo	5.98
5 mg Tirzepatide	50.24
10 mg Tirzepatide	73.61
15 mg Tirzepatide	78.24

Secondary outcomeNumber· Week 72

Percentage of Participants Who Achieve ≥20% Body Weight Reduction (Primary Treatment Period)

Group	Value (Percentage of Participants)
Placebo	1.26
5 mg Tirzepatide	31.62
10 mg Tirzepatide	55.48
15 mg Tirzepatide	62.88

Secondary outcomeLeast squares mean· Baseline, Week 72

Change From Baseline in Waist Circumference (Primary Treatment Period)

Group	Value (centimeters)	Spread
Placebo	-3.4	0.42
5 mg Tirzepatide	-14.6	0.41
10 mg Tirzepatide	-19.4	0.41
15 mg Tirzepatide	-19.9	0.41

Secondary outcomeLeast squares mean· Baseline, Week 72

Change From Baseline in Short Form Survey-36 Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score at Week 72 (Pooled Doses of Tirzepatide 10 mg and 15 mg) - Primary Treatment Period

Group	Value (score on a scale)	Spread
Placebo	1.7	0.27
Pooled 10 mg/15 mg Tirzepatide	4.0	0.18

Adverse events, as posted

Adverse events as posted: participants affected out of participants at risk, by group
Group	Deaths	Serious events	Other events
Placebo* Primary Treatment Period (Week 0-Week 72): Participants with normoglycemia or prediabetes at the time of randomization received QW SC doses of a matching placebo, administered over a period of 72 weeks. * Additional Treatment Period (Week 72-Week 176): At week 72, only participants who had prediabetes at the time of randomization and had completed the primary treatment period continued receiving the placebo dose SC QW until week 176. * Safety Follow-up Period: Participants who had completed or discontinued the primary treatment period were followed for safety for 4 weeks (weeks 72 - week 76), and those who had completed or discontinued the additional treatment period (prediabetes at randomization) were followed for 17 weeks (week 176 - week 193). No treatment was administered during this period.	4 / 643	53 / 643	315 / 643
5 mg Tirzepatide* Primary Treatment Period (Week 0-Week 72): Participants with normoglycemia or prediabetes at the time of randomization received QW SC doses of tirzepatide, starting at 2.5 mg and increasing by 2.5 mg every 4 weeks until reaching a dose of 5 mg, which was then maintained up to week 72. * Additional Treatment Period (Week 72-Week 176): At week 72, only participants who had prediabetes at the time of randomization and had completed the primary treatment period continued receiving the 5 mg tirzepatide dose SC QW until week 176. * Safety Follow-up Period: Participants who had completed or discontinued the primary treatment period were followed for safety for 4 weeks (weeks 72 - week 76), and those who had completed or discontinued the additional treatment period (prediabetes at randomization) were followed for 17 weeks (week 176 - week 193). No treatment was administered during this period.	4 / 630	57 / 630	443 / 630
10 mg Tirzepatide* Primary Treatment Period (Week 0-Week 72): Participants with normoglycemia or prediabetes at the time of randomization received QW SC doses of tirzepatide, starting at 2.5 mg and increasing by 2.5 mg every 4 weeks until reaching a dose of 10 mg, which was then maintained up to week 72. * Additional Treatment Period (Week 72-Week 176): At week 72, only participants who had prediabetes at the time of randomization and had completed the primary treatment period continued receiving the 10 mg tirzepatide dose SC QW until week 176. * Safety Follow-up Period: Participants who had completed or discontinued the primary treatment period were followed for safety for 4 weeks (weeks 72 - week 76), and those who had completed or discontinued the additional treatment period (prediabetes at randomization) were followed for 17 weeks (week 176 - week 193). No treatment was administered during this period.	3 / 636	60 / 636	451 / 636
15 mg Tirzepatide* Primary Treatment Period (Week 0-Week 72): Participants with normoglycemia or prediabetes at the time of randomization received QW SC doses of tirzepatide, starting at 2.5 mg and increasing by 2.5 mg every 4 weeks until reaching a dose of 15 mg, which was then maintained up to week 72. * Additional Treatment Period (Week 72-Week 176): At week 72, only participants who had prediabetes at the time of randomization and had completed the primary treatment period continued receiving the 15 mg tirzepatide dose SC QW until week 176. * Safety Follow-up Period: Participants who had completed or discontinued the primary treatment period were followed for safety for 4 weeks (weeks 72 - week 76), and those who had completed or discontinued the additional treatment period (prediabetes at randomization) were followed for 17 weeks (week 176 - week 193). No treatment was administered during this period.	2 / 630	50 / 630	429 / 630

Each cell reads participants affected / participants at risk, as the registry posted them.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies19

Studies that cite this trial.

Studies with results

15 studies on this page

Indexing hint: Randomized controlled trial · 2026

6 results

People With Lowest Physical Functioning Scores Showed Greatest Improvement After Tirzepatide Treatment.

Li et al. 2026Obesity (Silver Spring, Md.)cited by 2

PMID 41187013PMC12724063DOI 10.1002/oby.70067PUB-41187013

CC BY6 results

Download PDF See results (6)

Indexing hint: Randomized controlled trial · 2026

5 results

Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT.

Wadden et al. 2026Obesity (Silver Spring, Md.)cited by 3

PMID 41537305PMC12933222DOI 10.1002/oby.70122PUB-41537305

CC BY5 results

Download PDF See results (5)

Indexing hint: Randomized controlled trial · 2026

8 results

Efficacy and Safety of Tirzepatide in Japanese Participants With Obesity: A Subpopulation Analysis of the SURMOUNT-1 Trial.

Ishigaki et al. 2026Obesity (Silver Spring, Md.)

PMID 41612966PMC12933229DOI 10.1002/oby.70131PUB-41612966

CC BY8 results

Download PDF See results (8)

Indexing hint: Meta-analysis (pooled) · 2026

3 results

Weight Changes With Tirzepatide and Concomitant Weight-Inducing Medications: Post Hoc Analysis of Randomized Clinical Trials.

Galindo et al. 2026JAMA network open

PMID 41885866PMC13022736DOI 10.1001/jamanetworkopen.2026.3274PUB-41885866

Free to read · publisher termsCC BY-NC-ND3 results

Read at source See results (3)

Indexing hint: Randomized controlled trial · 2026

16 results

Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis.

Sattar et al. 2026Journal of the American College of Cardiologycited by 1

PMID 42233927DOI 10.1016/j.jacc.2026.04.044PUB-42233927

Full text at the publisher16 results

Publisher page See results (16)

Indexing hint: Randomized controlled trial · 2026

4 results

Tirzepatide Efficacy and Tolerability According to Early Weight Response: A Post Hoc Analysis of the SURMOUNT-1 and SURMOUNT-2 Trials.

Kokkinos et al. 2026Diabetes, obesity & metabolismcited by 2

PMID 42348366PMC13448863DOI 10.1111/dom.71009PUB-42348366

Free to read · publisher termsCC BY-NC-ND4 results

Read at source See results (4)

Indexing hint: Randomized controlled trial · 2025

6 results

Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: Results from the SURMOUNT-1 study.

Gudzune et al. 2025Diabetes, obesity & metabolismcited by 40

PMID 39497468PMC11701187DOI 10.1111/dom.16046PUB-39497468

Free to read · publisher termsCC BY-NC6 results

Read at source See results (6)

Indexing hint: Randomized controlled trial · 2025

7 results

Tirzepatide for Obesity Treatment and Diabetes Prevention.

Jastreboff et al. 2025The New England journal of medicinecited by 343

PMID 39536238DOI 10.1056/nejmoa2410819PUB-39536238

Full text at the publisher7 results

Publisher page See results (7)

Indexing hint: Randomized controlled trial · 2025

6 results

Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials.

Horn et al. 2025Clinical obesitycited by 12

PMID 39800653PMC12096058DOI 10.1111/cob.12734PUB-39800653

Free to read · publisher termsCC BY-NC-ND6 results

Read at source See results (6)

Indexing hint: Randomized controlled trial · 2025

14 results

Improvements in Cardiometabolic Risk Factors by Weight Reduction: A Post Hoc Analysis of Adults With Obesity Randomly Assigned to Tirzepatide.

Linetzky et al. 2025Annals of internal medicinecited by 10

PMID 40550133DOI 10.7326/annals-24-02623PUB-40550133

Full text at the publisher14 results

Publisher page See results (14)

Indexing hint: Randomized controlled trial · 2025

4 results

Weight reduction over time in tirzepatide-treated participants by early weight loss response: Post hoc analysis in SURMOUNT-1.

Ard et al. 2025Diabetes, obesity & metabolismcited by 13

PMID 40677091PMC12326891DOI 10.1111/dom.16554PUB-40677091

Free to read · publisher termsCC BY-NC4 results

Read at source See results (4)

Indexing hint: Randomized controlled trial · 2025

6 results

Early-Onset Obesity and Tirzepatide Treatment: A Post Hoc Analysis of the SURMOUNT Clinical Trials.

Gourgari et al. 2025Obesity (Silver Spring, Md.)cited by 4

PMID 40717199PMC12381612DOI 10.1002/oby.24348PUB-40717199

Free to read · publisher termsCC BY-NC-ND6 results

Read at source See results (6)

Indexing hint: Randomized controlled trial · 2024

8 results

Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial.

Krumholz et al. 2024Heart (British Cardiac Society)cited by 30

PMID 39084707PMC11420724DOI 10.1136/heartjnl-2024-324170PUB-39084707

Free to read · publisher termsCC BY-NC8 results

Read at source See results (8)

Indexing hint: Randomized controlled trial · 2023

8 results

Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT-1 trial.

Hankosky et al. 2023Diabetes, obesity & metabolismcited by 37

PMID 37700443DOI 10.1111/dom.15269PUB-37700443

Full text at the publisher8 results

Publisher page See results (8)

Indexing hint: Randomized controlled trial · 2022

6 results

Tirzepatide Once Weekly for the Treatment of Obesity.

Jastreboff et al. 2022The New England journal of medicinecited by 2,802

PMID 35658024DOI 10.1056/nejmoa2206038PUB-35658024

Full text at the publisher6 results

Publisher page See results (6)

More studies

4 studies on this page

PubMed tag: none · 2026

Evaluation of clinical relevance of weight nadirs and weight regain during 3 years of treatment with tirzepatide in participants with obesity or overweight and prediabetes.

Aronne et al. 2026Obesity pillars

PMID 42831032PMC13634289DOI 10.1016/j.obpill.2026.100333PUB-42831032

CC BY

Download PDF

PubMed tag: none · 2025

Kidney Parameters with Tirzepatide in Obesity with or without Type 2 Diabetes.

Heerspink et al. 2025Journal of the American Society of Nephrology : JASNcited by 17

PMID 40512543PMC12591676DOI 10.1681/asn.0000000764PUB-40512543

CC BY

Download PDF

PubMed tag: none · 2025

Visual demonstration of weight loss and health risk improvement with a dual GIP and GLP-1 receptor agonist.

Ramirez et al. 2025International journal of obesity (2005)cited by 1

PMID 40659850PMC12532576DOI 10.1038/s41366-025-01842-1PUB-40659850

Free to read · publisher termsCC BY-NC-ND

Read at source

PubMed tag: none · 2024

Tirzepatide Reduces 24-Hour Ambulatory Blood Pressure in Adults With Body Mass Index ≥27 kg/m²: SURMOUNT-1 Ambulatory Blood Pressure Monitoring Substudy.

de Lemos et al. 2024Hypertension (Dallas, Tex. : 1979)cited by 49

PMID 38314555PMC10956672DOI 10.1161/hypertensionaha.123.22022PUB-38314555

Free to read · publisher termsCC BY-NC-ND

Read at source

Eligibility

Who could join, as posted.

Sex: All
Age: from 18 Years
Healthy volunteers: Not accepted

Inclusion and exclusion criteria, as posted

Inclusion Criteria: * Body mass Index (BMI) ≥30 kilograms per square meter (kg/m²), or ≥27 kg/m² and previous diagnosis with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease * History of at least one unsuccessful dietary effort to lose body weight Exclusion Criteria: * Diabetes mellitus * Change in body weight greater than 5 kg within 3 months prior to starting study * Obesity induced by other endocrinologic disorders or monogenetic or syndromic forms of obesity * History of pancreatitis * Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2) * History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder within the last 2 years * Any lifetime history of a suicide attempt

PepBank is a research reference. Talk to a doctor before you use any peptide.

Overview

Registry summary

Interventions

Arms4

Primary outcomes2

Posted results

Primary outcome results

Adverse events, as posted

Studies19

Studies with results

People With Lowest Physical Functioning Scores Showed Greatest Improvement After Tirzepatide Treatment.

Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT.

Efficacy and Safety of Tirzepatide in Japanese Participants With Obesity: A Subpopulation Analysis of the SURMOUNT-1 Trial.

Weight Changes With Tirzepatide and Concomitant Weight-Inducing Medications: Post Hoc Analysis of Randomized Clinical Trials.

Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis.

Tirzepatide Efficacy and Tolerability According to Early Weight Response: A Post Hoc Analysis of the SURMOUNT-1 and SURMOUNT-2 Trials.

Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: Results from the SURMOUNT-1 study.

Tirzepatide for Obesity Treatment and Diabetes Prevention.

Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials.

Improvements in Cardiometabolic Risk Factors by Weight Reduction: A Post Hoc Analysis of Adults With Obesity Randomly Assigned to Tirzepatide.

Weight reduction over time in tirzepatide-treated participants by early weight loss response: Post hoc analysis in SURMOUNT-1.

Early-Onset Obesity and Tirzepatide Treatment: A Post Hoc Analysis of the SURMOUNT Clinical Trials.

Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial.

Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT-1 trial.

Tirzepatide Once Weekly for the Treatment of Obesity.

More studies

Evaluation of clinical relevance of weight nadirs and weight regain during 3 years of treatment with tirzepatide in participants with obesity or overweight and prediabetes.

Kidney Parameters with Tirzepatide in Obesity with or without Type 2 Diabetes.

Visual demonstration of weight loss and health risk improvement with a dual GIP and GLP-1 receptor agonist.

Tirzepatide Reduces 24-Hour Ambulatory Blood Pressure in Adults With Body Mass Index ≥27 kg/m2: SURMOUNT-1 Ambulatory Blood Pressure Monitoring Substudy.

Eligibility

Tirzepatide Reduces 24-Hour Ambulatory Blood Pressure in Adults With Body Mass Index ≥27 kg/m²: SURMOUNT-1 Ambulatory Blood Pressure Monitoring Substudy.